Optimization of RGD-containing cyclic peptides against αvβ3 integrin

Molecular Cancer Therapeutics

Volumn 15, Issue 2, 2016, Pages 232-240

  Wang, Yan ^a   Xiao, Wenwu ^a   Zhang, Yonghong ^b   Meza, Leah ^a   Tseng, Harry ^a   Takada, Yoshikazu ^c   Ames, James B ^a   Lam, Kit S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS PAN AMERICAN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPEPTIDE; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CONTROLLED STUDY; CYCLIZATION; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PHARMACOPHORE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN CONFORMATION; STATIC ELECTRICITY; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG DELIVERY SYSTEM; GLIOBLASTOMA; HUMAN; K-562 CELL LINE; METABOLISM; NUDE MOUSE; PROCEDURES; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; K562 CELLS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84960381048     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0544     Document Type: Article

References (35)

1. Humphries MJ. Integrin structure. Biochem Soc Trans 2000;28:311-39.
2. Luo BH, Springer TA. Integrin structures and conformational signaling. Curr Opin Cell Biol 2006;18:579-86.
3. Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol 2005;21:381-410.
4. Ruegg C, Alghisi GC. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. Recent Results Cancer Res 2010;180:83-101.
5. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
6. Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev 2010;29:223-37.
7. Liu Z, Wang F, Chen F. Integrin alpha (v) beta (3)-targeted cancer therapy. Drug Dev Res 2008;69:329-39.
8. Hodivala-Dilke K. Alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. Curr Opin Cell Biol 2008;20:514-9.
9. Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging 2012;39:S126-38.
10. Haubner R, Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci 2009;14:872-86.
11. Graham MM, Menda Y. Radiopeptide imaging and therapy in the United States. J Nucl Med 2012;52:56S-63S.
12. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011;52:42S-55S.
13. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49.
14. Tucker GC. Integrins: molecular targets in cancer therapy. Curr Oncol Rep 2006;8:96-103.
15. Reardon DA, Cheresh D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer 2011;2:1159-65.
16. Lam KS, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 1991;354:82-4.
17. Lam KS, Lebl M, Krchnak V. The "One-Bead-One-Compound" combinatorial library method. Chem Rev 1997;97:411-48.
18. Aina O, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Peptide Sci 2002;66:184-99.
19. Yao N, Xiao W, Marik J, Hyoung S, Lam KS. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. J Med Chem 2009;52:126-33.
20. Peng L, Liu R, Marik J, Takada Y, Lam KS. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol 2006;2:381-9.
21. Xiao W, Wang Y, Lau EY, Luo J, Yao N, Shi C, et al. The use of one-bead onecompound combinatorial library technology to discover high-affinity alphavbeta3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol Cancer Ther 2010;9:2714-23.
22. Grieco P, Carotenuto P, Campiglia P, Zampelli E, Pataccini R, Maggi CA, et al. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J Med Chem 2002;45:4391-4.
23. Legowska A, Debowski D, Lukajtis R, Wysocka M, Czaplewski C, Lesner A, et al. Implication of the disulfide bridge in trypsin inhibitor SFTI-1 in its interaction with serine proteinases. Bioorg Med Chem 2010;18:8188-93.
24. Schulz H, Du Vigneaud V. Synthesis of 1-L-penicillamine-oxytocin, 1-D-penicillamine-oxytocin, and 1-deaminopenicillamine-oxytocin, potent inhibitors of the oxytocic response of oxytocin. J Med Chem 1966;9:647-50.
25. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984;309:30-3.
26. Kumagai H, Tajima M, Ueno Y, CGiga-Hama Y, Ohba M. Effect of cyclic RGD peptide oncell adhesion and tumor metastasis. Biochem Biophys Res Commun 1991;177:74-82.
27. Richardson JS. The anatomy and taxonomy of protein structure. Adv Protein Chem 1981;34:167-339.
28. Elbaz Y, Salomon T, Schuldiner S. Identification of a glycine motif required for packing in EmrE, a multidrug transporter from Escherichia coli. J Biol Chem 2008;283:12276-83.
29. Chatterjee J, Gilon C, Hoffman A, Kessler H. N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res 2008;41:1331-42.
30. Rajeswaran WG, Murphy WA, Taylor JE, Coy DH. Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist. J Med Chem 2001;44:1305-11.
31. Zhang S, Govender T, Norstrom T, Arvidsson PI. An improved synthesis of Fmoc-N-methyl-alpha-amino acids. J Org Chem 2005;70:6918-20.
32. Liu R, Wang X, Song A, Bao T, Lam KS. Development and applications of topologically segregated bilayer beads in one-bead one-compound combinatorial libraries. QSAR Comb Sci 2005;24:1127-40.
33. Lau D, Gio L, Liu R, Song A, Shao C, Lam KS. Identifying peptide ligands for cell surface receptors using cell-growth-on-bead assay and one-bead onecompound combinatorial library. Biotechnol Lett 2002;24:497-500.
34. Schechter B, Colas C, Burakova T, Wilchek M. Renal accumulation of streptavidin: potential use for targeted therapy to the kidney. Kidney Int 1995;47:1327-35.
35. Schechter B, Silberman R, Arnon R, Wilchek M. Tissue distribution ofavidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur J Biochem 1990;189:327-31.